The Effect of Statin Therapy on Inflammatory Biomarkers: A Systematic Review

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2021 Nov 1

PMID 34722051

Citations 6

Authors

Matthew C Proute

Nageshwar Kothur

Petros Georgiou

Tatsiana Serhiyenia

Wangpan Shi

Mina E Kerolos

Roshini Pradeep

Aqsa Akram

Safeera Khan

Affiliations

Soon will be listed here.

Abstract

3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors are commonly used drugs in the management of elevated lipid levels and cardiovascular disease. In cardiovascular diseases, among other common chronic conditions, inflammatory biomarkers are used to monitor disease progression and the risk of recurrent adverse events. We explored whether or not there was a positive effect on these biomarkers using HMG-CoA reductase inhibitors. The systematic review was conducted by gathering relevant papers mainly from three databases, identified through a generated Medical Subject Headings (MeSH) strategy. Identification of papers was subsequently followed by applying a selected inclusion and exclusion criteria to narrow the papers chosen for review. Post the application of stipulated criteria, 12 papers remained. They were subsequently assessed for risk of bias using a Cochrane risk analysis tool, identifying most as having some concerns of bias or low risk of bias. We found that HMG-CoA reductase inhibitors exhibit both a lipid-lowering effect addition to an anti-inflammatory effect.

Citing Articles

Statins-Beyond Their Use in Hypercholesterolemia: Focus on the Pediatric Population.

Spoiala E, Cinteza E, Vatasescu R, Vlaiculescu M, Moisa S Children (Basel). 2024; 11(1).

PMID: 38255430 PMC: 10813894. DOI: 10.3390/children11010117.

Statins and thyroid eye disease (TED): a systematic review.

Malboosbaf R, Maghsoomi Z, Emami Z, Khamseh M, Azizi F Endocrine. 2024; 85(1):11-17.

PMID: 38194219 DOI: 10.1007/s12020-023-03680-5.

Targeting inflammation in atherosclerosis: overview, strategy and directions.

Waksman R, Merdler I, Case B, Waksman O, Porto I EuroIntervention. 2024; 20(1):32-44.

PMID: 38165117 PMC: 10756224. DOI: 10.4244/EIJ-D-23-00606.

Current Medical Therapy and Revascularization in Peripheral Artery Disease of the Lower Limbs: Impacts on Subclinical Chronic Inflammation.

Cecchini A, Biscetti F, Manzato M, Sasso L, Rando M, Nicolazzi M Int J Mol Sci. 2023; 24(22).

PMID: 38003290 PMC: 10671371. DOI: 10.3390/ijms242216099.

Effect of Statins on the Inflammatory Markers in Patients with Coronary Artery Disease.

Premnath S, Nanda S, Ray L, Arokiaraj M J Lab Physicians. 2023; 15(4):498-502.

PMID: 37780883 PMC: 10539054. DOI: 10.1055/s-0043-1768167.

References

Aranow C, Cush J, Bolster M, Striebich C, DallEra M, Mackay M . A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. Rheumatology (Oxford). 2019; 59(7):1505-1513. PMC: 7310095. DOI: 10.1093/rheumatology/kez471. View

Bray C, Bell L, Liang H, Haykal R, Kaiksow F, Mazza J . Erythrocyte Sedimentation Rate and C-reactive Protein Measurements and Their Relevance in Clinical Medicine. WMJ. 2017; 115(6):317-21. View

Stroes E . Statins and LDL-cholesterol lowering: an overview. Curr Med Res Opin. 2005; 21 Suppl 6:S9-16. DOI: 10.1185/030079905X59102. View

Flannagan K, Sjaarda L, Hill M, Connell M, Zolton J, Perkins N . Pilot randomized trial of short-term changes in inflammation and lipid levels during and after aspirin and pravastatin therapy. Reprod Health. 2019; 16(1):132. PMC: 6720394. DOI: 10.1186/s12978-019-0794-6. View

Bedi P, Chalmers J, Graham C, Clarke A, Donaldson S, Doherty C . A Randomized Controlled Trial of Atorvastatin in Patients With Bronchiectasis Infected With Pseudomonas Aeruginosa: A Proof of Concept Study. Chest. 2017; 152(2):368-378. DOI: 10.1016/j.chest.2017.05.017. View

Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E . High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation. 2018; 137(19):1997-2009. PMC: 5959207. DOI: 10.1161/CIRCULATIONAHA.117.032615. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021; 10(1):89. PMC: 8008539. DOI: 10.1186/s13643-021-01626-4. View

Fuentes-Orozco C, Garcia-Salazar S, Gomez-Navarro B, Gonzalez-Espinoza E, Zepeda-Gonzalez A, Ramirez-Robles J . Anti-Inflammatory Effect of Atorvastatin on the Kidney Graft of Living Donor Transplants. Ann Transplant. 2018; 23:442-449. PMC: 6248064. DOI: 10.12659/AOT.908521. View

Kitagawa K, Hosomi N, Nagai Y, Kagimura T, Ohtsuki T, Origasa H . Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS. J Atheroscler Thromb. 2017; 24(10):1039-1047. PMC: 5656766. DOI: 10.5551/jat.39354. View

10.

Saggini A, Anogeianaki A, Maccauro G, Tete S, Salini V, Caraffa A . Cholesterol, cytokines and diseases. Int J Immunopathol Pharmacol. 2011; 24(3):567-81. DOI: 10.1177/039463201102400303. View

11.

Rodriguez F, Maron D, Knowles J, Virani S, Lin S, Heidenreich P . Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2016; 2(1):47-54. DOI: 10.1001/jamacardio.2016.4052. View

12.

Wu N, Guo Y, Zhu C, Gao Y, Zhao X, Sun D . Comparison of statin plus ezetimibe with double-dose statin on lipid profiles and inflammation markers. Lipids Health Dis. 2018; 17(1):265. PMC: 6260646. DOI: 10.1186/s12944-018-0909-z. View

13.

Barale C, Frascaroli C, Senkeev R, Cavalot F, Russo I . Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia. Biomed Res Int. 2018; 2018:6508709. PMC: 6191949. DOI: 10.1155/2018/6508709. View

14.

Ramos R, Comas-Cufi M, Marti-Lluch R, Ballo E, Ponjoan A, Alves-Cabratosa L . Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study. BMJ. 2018; 362:k3359. PMC: 6123838. DOI: 10.1136/bmj.k3359. View

15.

Kitas G, Nightingale P, Armitage J, Sattar N, Belch J, Symmons D . A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019; 71(9):1437-1449. PMC: 6771601. DOI: 10.1002/art.40892. View

16.

Zhao Y, Peng R, Zhao W, Liu Q, Guo Y, Zhao S . Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease. Medicine (Baltimore). 2017; 96(7):e6104. PMC: 5319516. DOI: 10.1097/MD.0000000000006104. View

17.

Kawada-Watanabe E, Yamaguchi J, Sekiguchi H, Arashi H, Ogawa H, Hagiwara N . Targeting high-sensitivity C-reactive protein levels in acute coronary syndrome patients undergoing contemporary lipid-lowering therapy: a sub-analysis of the HIJ-PROPER trial. J Cardiol. 2019; 75(5):500-506. DOI: 10.1016/j.jjcc.2019.09.015. View

18.

Westin G, Armstrong E, Bang H, Yeo K, Anderson D, Dawson D . Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol. 2013; 63(7):682-690. PMC: 3944094. DOI: 10.1016/j.jacc.2013.09.073. View

19.

Fang M, Qian Q, Zhao Z, Zhu L, Su J, Li X . High-Sensitivity C-Reactive Protein Combined with Low-Density Lipoprotein Cholesterol as the Targets of Statin Therapy in Patients with Acute Coronary Syndrome. Int Heart J. 2018; 59(2):300-306. DOI: 10.1536/ihj.17-101. View